These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27917591)

  • 1. The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism.
    Möllmann J; Kahles F; Lebherz C; Kappel B; Baeck C; Tacke F; Werner C; Federici M; Marx N; Lehrke M
    Diabetes Obes Metab; 2017 Apr; 19(4):496-508. PubMed ID: 27917591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways.
    Kwak HJ; Park KM; Choi HE; Chung KS; Lim HJ; Park HY
    Cell Signal; 2008 May; 20(5):803-14. PubMed ID: 18276108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-β1 pathway: therapeutic role of roflumilast.
    Tao X; He H; Peng J; Xu R; Fu J; Hu Y; Li L; Yang X; Feng X; Zhang C; Zhang L; Yu X; Shen A; Huang K; Fu Q
    Pharmacol Res; 2022 Jan; 175():106004. PubMed ID: 34826603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner.
    Lehrke M; Kahles F; Makowska A; Tilstam PV; Diebold S; Marx J; Stöhr R; Hess K; Endorf EB; Bruemmer D; Marx N; Findeisen HM
    J Mol Cell Cardiol; 2015 Apr; 81():23-33. PubMed ID: 25640159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice.
    Wang B; Zhu X; Yu S; Xue H; Deng L; Zhang Y; Zhang Y; Liu Y
    Biochem Biophys Res Commun; 2024 Aug; 722():150170. PubMed ID: 38797152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
    Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
    Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL/6J mice.
    Liu X; Hao PD; Yang MF; Sun JY; Mao LL; Fan CD; Zhang ZY; Li DW; Yang XY; Sun BL; Zhang HT
    Psychopharmacology (Berl); 2017 Aug; 234(16):2409-2419. PubMed ID: 28477089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pu-erh tea extract ameliorates high-fat diet-induced nonalcoholic steatohepatitis and insulin resistance by modulating hepatic IL-6/STAT3 signaling in mice.
    Cai X; Fang C; Hayashi S; Hao S; Zhao M; Tsutsui H; Nishiguchi S; Sheng J
    J Gastroenterol; 2016 Aug; 51(8):819-29. PubMed ID: 26794005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roflumilast ameliorates cognitive impairment in APP/PS1 mice via cAMP/CREB/BDNF signaling and anti-neuroinflammatory effects.
    Feng H; Wang C; He W; Wu X; Li S; Zeng Z; Wei M; He B
    Metab Brain Dis; 2019 Apr; 34(2):583-591. PubMed ID: 30610438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi.
    Susuki-Miyata S; Miyata M; Lee BC; Xu H; Kai H; Yan C; Li JD
    Proc Natl Acad Sci U S A; 2015 Apr; 112(14):E1800-9. PubMed ID: 25831493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin E2.
    Ikari J; Michalski JM; Iwasawa S; Gunji Y; Nogel S; Park JH; Nelson AJ; Farid M; Wang X; Schulte N; Basma H; Toews ML; Feghali-Bostwick C; Tenor H; Liu X; Rennard SI
    Am J Respir Cell Mol Biol; 2013 Oct; 49(4):571-81. PubMed ID: 23656623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roflumilast partially reverses smoke-induced mucociliary dysfunction.
    Schmid A; Baumlin N; Ivonnet P; Dennis JS; Campos M; Krick S; Salathe M
    Respir Res; 2015 Oct; 16():135. PubMed ID: 26521141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roflumilast enhances cisplatin-sensitivity and reverses cisplatin-resistance of ovarian cancer cells via cAMP/PKA/CREB-FtMt signalling axis.
    Gong S; Chen Y; Meng F; Zhang Y; Li C; Zhang G; Huan W; Wu F
    Cell Prolif; 2018 Oct; 51(5):e12474. PubMed ID: 30069985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice.
    Vollert S; Kaessner N; Heuser A; Hanauer G; Dieckmann A; Knaack D; Kley HP; Beume R; Weiss-Haljiti C
    Diabetologia; 2012 Oct; 55(10):2779-2788. PubMed ID: 22790061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amlexanox reversed non-alcoholic fatty liver disease through IKKε inhibition of hepatic stellate cell.
    He Q; Xia X; Yao K; Zeng J; Wang W; Wu Q; Tang R; Zou X
    Life Sci; 2019 Dec; 239():117010. PubMed ID: 31672578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct Inhibitory Effect of the PDE4 Inhibitor Roflumilast on Neutrophil Migration in Chronic Obstructive Pulmonary Disease.
    Dunne AE; Kawamatawong T; Fenwick PS; Davies CM; Tullett H; Barnes PJ; Donnelly LE
    Am J Respir Cell Mol Biol; 2019 Apr; 60(4):445-453. PubMed ID: 30395484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Nonhuman Primate PET Study: Measurement of Brain PDE4 Occupancy by Roflumilast Using (R)-[
    Takano A; Uz T; Garcia-Segovia J; Tsai M; Lahu G; Amini N; Nakao R; Jia Z; Halldin C
    Mol Imaging Biol; 2018 Aug; 20(4):615-622. PubMed ID: 29441434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platycodon grandiflorus Root Extract Attenuates Body Fat Mass, Hepatic Steatosis and Insulin Resistance through the Interplay between the Liver and Adipose Tissue.
    Kim YJ; Choi JY; Ryu R; Lee J; Cho SJ; Kwon EY; Lee MK; Liu KH; Rina Y; Sung MK; Choi MS
    Nutrients; 2016 Aug; 8(9):. PubMed ID: 27589792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses.
    Vanmierlo T; Creemers P; Akkerman S; van Duinen M; Sambeth A; De Vry J; Uz T; Blokland A; Prickaerts J
    Behav Brain Res; 2016 Apr; 303():26-33. PubMed ID: 26794595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus.
    Wouters EF; Bredenbröker D; Teichmann P; Brose M; Rabe KF; Fabbri LM; Göke B
    J Clin Endocrinol Metab; 2012 Sep; 97(9):E1720-5. PubMed ID: 22723325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.